Daily Newsletter

13 October 2023

Daily Newsletter

13 October 2023

Metabolon rolls out new panels for liver fibrosis and kidney function

The Liver Fibrosis Discovery Panel helps analyse 105 metabolites across multiple biological processes.

RanjithKumar Dharma October 13 2023

Metabolon has introduced new liver fibrosis and kidney function discovery panels for revealing disease mechanisms and enabling research.

The new panels are part of the Metabolon Discover portfolio of metabolomics services and are intended to evaluate several metabolites across diverse biological pathways that are associated with kidney disease and liver fibrosis.

Leveraging new visualisation tools, the panels will allow researchers to compare results across different data sets for detecting and understanding statistically significant change impacts in metabolite abundance.

The liver fibrosis discovery panel helps analyse 105 metabolites across multiple biological processes.

Using this panel, researchers will be able to detect the suitable markers connected to liver fibrosis and address key challenges regarding drug discovery and testing, personalised medicine and mechanistic insights.

The kidney function discovery panel has been designed to analyse 84 metabolites associated with biochemical processes that affect kidney function. It will help researchers in differentiating the diverse spectrum of kidney disease.

Metabolon chief scientific officer Rangaprasad Sarangarajan said: “Our new Liver Fibrosis and Kidney Function Discovery Panels seek to reveal fundamental metabolic changes, thereby facilitating our understanding of the underlying mechanisms of these diseases.

“Metabolon is committed to providing insights that can ultimately lead to the creation of tools improving patient outcomes through earlier detection, better monitoring and improved treatments.”

Both chronic liver and kidney diseases can be treated if detected early, but more research is required to understand the underlying causes of these ailments.

Healthcare companies are hesitant to invest in the metaverse

Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close